Allergo Journal International最新文献

{"title":"Systemic therapy of atopic dermatitis with Janus kinase inhibitors","authors":"Thomas Bieber MDRA","doi":"10.1007/s40629-025-00345-9","DOIUrl":"10.1007/s40629-025-00345-9","url":null,"abstract":"<div><h3>Background</h3><p>Over the last 8 years, the treatment of atopic dermatitis (AD) has been revolutionized by the development and approval of novel systemic therapies. In addition to the biologics dupilumab, tralokinumab, lebrikizumab, and nemolizumab, the three Janus kinase inhibitors (JAKi) baricitinib, abrocitinib, and upadacitinib are now also available.</p><h3>Methods and results</h3><p>A selection of the most important publications on the approved JAKi for the systemic treatment of AD and their statements were used as the basis for this review.</p><h3>Conclusion</h3><p>Systemic JAKi have become established as a promising therapeutic option in the guidelines for the treatment of AD. They specifically block the JAK signaling pathways involved in the inflammatory response and provide rapid and effective relief of the inflammatory reaction as well as the symptoms such as itching and pain. Compared to the class of biologics, they have a broader effect on various cytokines. Despite very good efficacy, there are some safety concerns, which is why a careful risk–benefit assessment is required in accordance with European Medicines Agency recommendations.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 6","pages":"167 - 172"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Update on conventional therapy for atopic dermatitis","authors":"Lisa Anna Perzynski","doi":"10.1007/s40629-025-00346-8","DOIUrl":"10.1007/s40629-025-00346-8","url":null,"abstract":"<div><p>Atopic dermatitis (AD) is the most common chronic inflammatory skin disease and requires therapy that is individualized, yet also based on the current guidelines. This narrative review gives an update on the conventional therapy of AD depending on severity according to the German S3 guideline on AD. AD severity is graded as mild, moderate, and severe AD. Consequent topical basic therapy and avoidance of potential trigger factor is recommended for all patients. Basic therapy should be applied not only during a flare, but also to clear skin to prevent worsening; furthermore, mild/moderate eczema should receive anti-inflammatory therapy with topical corticosteroids/calcineurin inhibitors. Systemic therapy is indicated in moderate-to-severe AD with insufficient response to other measures, if applicable, also ultraviolet therapy. Systemic therapies are grouped into conventional and targeted therapies (biologics and Janus kinase inhibitors). Systemic corticosteroids should only be used as rescue therapy for 3 weeks maximum. Targeted therapies in AD have the highest recommendation grade for long-term therapy. Cyclosporin A (CsA), azathioprine (AZT), methotrexate (MTX), and mycophenolate mofetil (MMF) belong to the conventional steroid-sparing therapies. However, only CsA is licensed for AD. MTX should be and MMF might be considered for AD according to the German S3 guideline, while AZT may be considered in adults.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 6","pages":"173 - 179"},"PeriodicalIF":0.0,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00346-8.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biologics in the treatment of atopic dermatitis: approved active substances and monoclonal antibodies in advanced clinical trials","authors":"Svenja Royeck","doi":"10.1007/s40629-025-00340-0","DOIUrl":"10.1007/s40629-025-00340-0","url":null,"abstract":"<div><p>Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in industrialized countries and is characterized by heterogeneous (endo)phenotypes and a high disease burden. In Europe, four biologics and three oral Janus kinase (JAK) inhibitors are currently approved by the European Medicines Agency (EMA) for the treatment of moderate to severe AD in adolescents (≥ 12 years) and adults: dupilumab (anti-interleukin [IL]-4Rα; 2017), tralokinumab (anti-IL-13; 2021), lebrikizumab (anti-IL-13; 2023) and nemolizumab (anti-IL-31Rα; 2024) as well as the JAK inhibitors baricitinib (JAK 1/2; 2020), upadacitinib (JAK 1; 2021) and abrocitinib (JAK 1; 2022). Among the abovementioned therapies, baricitinib for moderate and severe AD from the second year of life and dupilumab for severe AD from the sixth month of life are already two approved systemic therapies for early childhood. This narrative review provides an update on the biologics currently approved for treatment of moderate and severe AD. It also provides a brief overview of monoclonal antibodies currently in phase III clinical trials and future issues and opportunities for immunomodulatory systemic therapies for AD.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 6","pages":"159 - 166"},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00340-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037328","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic approaches to food allergies","authors":"Nora Knappe,&nbsp; Katja Nemat,&nbsp;Christian Vogelberg","doi":"10.1007/s40629-025-00337-9","DOIUrl":"10.1007/s40629-025-00337-9","url":null,"abstract":"<div><p>This paper provides an overview of the various treatment options for food allergies, including the introduction of extensively heated foods, immunotherapies, food ladders, and pharmacological treatments.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 5","pages":"134 - 139"},"PeriodicalIF":0.0,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00337-9.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145166177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology of food allergy","authors":"Alisa Arens,&nbsp;Lars Lange,&nbsp;Kristina Stamos","doi":"10.1007/s40629-025-00336-w","DOIUrl":"10.1007/s40629-025-00336-w","url":null,"abstract":"<div><p>Food allergies are associated with considerable psychosocial stress and restrictions in quality of life. While parents often report food allergies in their children, studies show that the perceived prevalence is often higher than the actual diagnosed prevalence. Epidemiological studies show an increasing prevalence worldwide, with significant regional differences. In Europe, self-reported prevalence varies widely, from less than 1% to over 10%, depending on region, age and foods analysed. In North America and Northern Europe, peanut and egg allergies are more common, while shellfish and fish allergies dominate in Asia. Environmental factors, ethnicity, genetic predisposition, dietary habits and socioeconomic conditions play a significant role in the development and distribution of food allergies. These factors must be taken into account when developing prevention and treatment strategies.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 5","pages":"121 - 126"},"PeriodicalIF":0.0,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00336-w.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145163557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral contact allergies: a comprehensive narrative review on etiology, clinical manifestations, diagnosis, and management","authors":"Sreepreeti Champatyray BDS MDS.,&nbsp;Saurjya Ranjan Das MBBS MD,&nbsp;Dhiren Kumar Panda M.Sc. Ph.D","doi":"10.1007/s40629-025-00338-8","DOIUrl":"10.1007/s40629-025-00338-8","url":null,"abstract":"<div><h3>Purpose</h3><p>Oral contact allergies (OCAs) are increasingly recognized in dental practice and commonly manifest as oral lichenoid reactions (OLRs), allergic contact stomatitis (ACS), and burning mouth syndrome (BMS). This narrative review aims to synthesize current knowledge on etiological factors, diagnostic challenges, and management strategies to enhance clinical guidance.</p><h3>Methods</h3><p>A comprehensive literature search was conducted across major medical and dental databases focusing on studies from 2000–2024 addressing OCAs related to dental materials, oral hygiene products, and food allergens. Emphasis was placed on clinical features, diagnostic methodologies—including patch testing and emerging biomarkers—and therapeutic approaches documented in recent literature.</p><h3>Results</h3><p>Common precipitants of OCAs include metals such as nickel, mercury, cobalt, and acrylates, with prevalence estimates ranging from 5 to 20%, predominantly affecting middle-aged women. Diagnosis primarily relies on clinical evaluation supported by patch testing, though emerging techniques such as salivary biomarkers and histopathological analyses show promise. Management centers on allergen avoidance and topical corticosteroids, with immunotherapy approaches such as sublingual immunotherapy (SLIT) gaining preliminary support despite a lack of comprehensive guidelines.</p><h3>Conclusion</h3><p>Enhanced detection and recognition of OCAs are critical to improving patient outcomes and quality of life. Dentists should incorporate OCAs into differential diagnoses for chronic oral mucosal disorders and remain informed about advances in diagnostics and therapeutics.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 6","pages":"180 - 185"},"PeriodicalIF":0.0,"publicationDate":"2025-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145037181","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Severity assessment of food allergies according to DEFASE criteria in the German healthcare system (d-DEFASE)","authors":"Stefania Arasi,&nbsp;Lars Lange,&nbsp;Katharina Blümchen,&nbsp;Nora Knappe,&nbsp;Katja Nemat,&nbsp;Randolf Brehler,&nbsp;Stefani Röseler,&nbsp;Michael Gerstlauer,&nbsp;Jan Hagemann,&nbsp;Friederike Bärhold,&nbsp;Ingrid Casper,&nbsp;Philippe Eigenmann,&nbsp;Alessandro Fiocchi,&nbsp;Ludger Klimek,&nbsp; Christian Vogelberg","doi":"10.1007/s40629-025-00334-y","DOIUrl":"10.1007/s40629-025-00334-y","url":null,"abstract":"<p>There is currently no standardized evaluation system in Germany for defining and classifying the severity of IgE-mediated food allergies (FA). Following the development of the international classification system named DEFASE (Definition of Food Allergy Severity), this evaluation system is now also being introduced in Germany and its applicability in the German healthcare system is being tested.</p><p>An international consensus was reached on DEFASE through a two-stage process (systematic literature review followed by an e‑Delphi).</p><p>The DEFASE score is the first comprehensive classification of the severity of a FA that takes into account not only the severity of an individual reaction, but the entire scenario of the disease, including the clinical features alongside patient’s reported outcomes and economic burden. It is important that an international consensus has been reached on a scoring system for FA, which can now also be used in Germany as d‑DEFASE. The scoring system is currently tested in research projects to be introduced soon into clinical practice, targeting these models to various food allergenic sources, populations, and settings.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 5","pages":"113 - 120"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00334-y.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145167377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations for allergy-friendly urban planting in the context of climate change","authors":"Karl-Christian Bergmann,&nbsp;Wolfgang Straff,&nbsp;Hans-Guido Mücke,&nbsp;Katarina Stevanovic,&nbsp;Torsten Zuberbier","doi":"10.1007/s40629-025-00332-0","DOIUrl":"10.1007/s40629-025-00332-0","url":null,"abstract":"<div><p>Climate change is altering temperature patterns and pollen exposure, particularly in cities. Rising summer temperatures are reducing the well-being of urban populations: however, this impact can be partially reduced by suitable planting. Primarily, the issue is that exposure to pollen leads to sensitization and allergic symptoms more frequently in cities than in rural areas. Also, individuals with pollen allergies, especially those reactive to tree (hazelnut, alder, birch, ash) and grass pollen, experience more severe symptoms in cities due to the interaction of pollen with air pollutants. To counteract this trend, urban planting should prioritize nonallergenic, or low-allergenic plant species. Here we present a table categorizing tree species based on their allergic potential: (a) species that should not be planted under any circumstances, (b) species that should be avoided but can be planted with caution, (c) species currently regarded as allergy friendly. Adopting these recommendations should counteract a further increase in tree pollen exposure and, thus, the frequency of sensitization, especially in residential areas. This paper serves as an update of a previous recommendation for planting new trees in public spaces with allergy considerations, incorporating the 2022 GALK street tree list, which is maintained by the “Urban Trees Working Group”.</p></div>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 4","pages":"95 - 103"},"PeriodicalIF":0.0,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00332-0.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145161166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful treatment of anaphylaxis to sulfites with sulfite-containing adrenaline auto-injector","authors":"Jolien Isabel Kessels MD,&nbsp;Jan Gutermuth MD PhD,&nbsp;Martine Grosber MD","doi":"10.1007/s40629-025-00328-w","DOIUrl":"10.1007/s40629-025-00328-w","url":null,"abstract":"<p>Anaphylaxis is a potentially life-threatening type 1 hypersensitivity reaction mediated by specific IgE. Culprit allergens frequently include foods, drugs, and insect venom. Sulfites are widely used as additives in food processing but also occur naturally in high concentrations in certain foods. Additionally, they are added as preservatives to aqueous cosmetic and medical solutions. Sulfites have been reported to cause a variety of allergic reactions including anaphylaxis. Here, we present a case of a patient with repetitive anaphylactic reactions to sulfites in food. An allergy workup showed a positive prick test to sodium metabisulfite and a positive oral provocation test. Our patient was successfully treated for anaphylaxis with a sulfite-containing adrenaline auto-injector, suggesting the benefits of adrenaline outweigh the theoretical risks in an acute anaphylactic setting.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 4","pages":"107 - 109"},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145166377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mastocytosis in the age of precision medicine","authors":"Frank Siebenhaar,&nbsp;Randolf Brehler,&nbsp;Deborah Christen,&nbsp;Karin Hartmann,&nbsp;Sabine Altrichter,&nbsp;Marcus Joest,&nbsp;Kristin aufm Kampe,&nbsp;Claudia C. V. Lang,&nbsp;Undine Lippert,&nbsp;Norbert Mülleneisen,&nbsp;Hagen Ott,&nbsp;Jens Panse,&nbsp;Polina Pyatilova,&nbsp;Peter Schmid-Grendelmeier,&nbsp;Petra Staubach,&nbsp;Stefani Röseler,&nbsp;Franziska Ruëff,&nbsp;Dagmar von Bubnoff,&nbsp;Nikolas von Bubnoff,&nbsp;Nicola Wagner,&nbsp;Torsten Zuberbier,&nbsp;Marcus Maurer,&nbsp;Friederike Bärhold,&nbsp;Ludger Klimek,&nbsp;Knut Brockow","doi":"10.1007/s40629-025-00327-x","DOIUrl":"10.1007/s40629-025-00327-x","url":null,"abstract":"<p>Mastocytosis encompasses a spectrum of clonal mast cell disorders characterized by the proliferation and accumulation of atypical mast cells in various organs, including the skin, bone marrow, and gastrointestinal tract. Initially described in 1869 as a cutaneous manifestation, the systemic variant (SM), involving additional organs, was documented in 1949. Clinical distinctions are made between indolent SM (ISM), where mediator-related symptoms predominate, and more aggressive forms, in which organ dysfunction is the primary concern. In recent decades, there has been continuous progress in elucidating the pathogenesis, classification, and management of mastocytosis, aided by specialized networks such as the European Competence Network Mastocytosis (ECNM) and the German Competence Network on Mastocytosis (Kompetenznetzwerk Mastozytose e. V.). A significant therapeutic advancement has been the development of targeted tyrosine kinase inhibitors, including midostaurin and avapritinib, which have been utilized for several years in treating aggressive SM. Recently, avapritinib in lower dosage was also approved for ISM patients with moderate to severe symptoms. For patients with milder forms of ISM, a symptom-oriented basic therapy is recommended. The diagnosis of SM requires interdisciplinary collaboration and strict adherence to established diagnostic criteria. Moreover, innovative patient-centered approaches, such as the MASTHAVE® app, support ongoing follow-up and have the potential to enhance quality of life. Long-term research efforts are increasingly directed toward developing personalized therapies that target the molecular mechanisms underlying the disease.</p>","PeriodicalId":37457,"journal":{"name":"Allergo Journal International","volume":"34 3","pages":"57 - 68"},"PeriodicalIF":0.0,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s40629-025-00327-x.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143883597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}